Seminar - Results of the prostate cancer intervention versus observation trial

19 September 2012

Speaker:Professor Michael J Barry, Clinical Professor of Medicine, Harvard Medical School and President, Informed Medical Decisions Foundation


Results of the Prostate cancer Intervention Versus Observation Trial (PIVOT): What are the Implications for Screening?
The PIVOT trial randomized 731 men (mean age 67, median PSA 7.8 ng/mL) with clinically localized prostate cancer to a strategy of observation or radical prostatectomy. Most men had their cancers detected through PSA screening, and about half were stage T1c. After a median follow-up of 10 years almost half of men had died. In the entire study population there was no significant difference in overall or prostate cancer mortality, and point estimates of absolute differences in mortality between groups were less than 3%. However, in subgroup analyses, there was evidence for differential effects, particularly for men with higher versus lower PSA levels. Should the PIVOT results further condemn PSA screening, or do they provide a rationale for conducting screening in a way that minimizes overdiagnosis and overtreatment while preserving most of any benefit?

RSVP Sandwich lunch will be provided from 12.30.Please RSVP by Monday 17 September

Hosted by Screening & Test Evaluation Program (STEP), School of Public Health

Time: 1 - 2pm

Location: Chemistry Lecture Theatre 4, University of Sydney

Phone: 02 9114 1228

Email: 3b291b772129100b092c541e2b4b41123c3c1c534611